HIGHER Corporation Recognized as 'Baby Unicorn' for Global Growth Potential
TL;DR
HIGHER Corporation's recognition as a 'Baby Unicorn' and 'First Penguin' company offers a competitive edge in securing global contracts and funding, positioning it as a leader in the medical device industry.
HIGHER Corporation's HILO WAVE® technology uses a dual-formulation of hyaluronic acid to stimulate skin regeneration, approved as a Class 4 medical device for its safety and effectiveness.
HIGHER Corporation's innovations in medical devices and global expansion efforts contribute to advancements in aesthetic medicine, improving skin health and confidence worldwide.
Discover how HIGHER Corporation's HILO WAVE® is revolutionizing skin care with its unique hyaluronic acid formulation, offering immediate and lasting results.
Found this article helpful?
Share it with your network and spread the knowledge!
HIGHER Corporation, a pioneering medical device startup, has recently been honored as a 'Baby Unicorn' by the Ministry of SMEs and Startups and recognized as a 'First Penguin' company by the Korea Credit Guarantee Fund. These accolades underscore the company's advanced technological innovations and its robust potential for global expansion, particularly in the aesthetic medical device sector.
The 'Baby Unicorn' program is a strategic initiative aimed at fostering high-potential startups with the capability to achieve global success. Through this program, HIGHER Corporation gains access to tailored support, funding opportunities, and strategic guidance, which are crucial for accelerating its growth trajectory. The selection process this year was notably competitive, highlighting the vibrant and dynamic nature of the Korean startup ecosystem.
At the core of HIGHER Corporation's product lineup is HILO WAVE®, a next-generation bio-stimulator that utilizes a unique dual-formulation of hyaluronic acid to enhance skin elasticity and hydration. Approved as a Class 4 medical device in Korea, HILO WAVE® stands out for its ability to stimulate the skin's natural regeneration process, offering both immediate and lasting results.
The company's global business strategy is already yielding significant results, with supply contracts secured in several Southeast Asian countries and ongoing negotiations in Brazil and China. Furthermore, HIGHER Corporation is preparing for CE MDR certification to penetrate the European market, further solidifying its global presence.
With the support from the 'Baby Unicorn' program, including financial incentives and market development funds, HIGHER Corporation is well-positioned to strengthen its foothold in both domestic and international markets. The recognition as a 'Baby Unicorn' and 'First Penguin' company not only validates HIGHER Corporation's innovative approach but also sets the stage for its ascent as a leading global unicorn in the aesthetic medical device industry.
Curated from 24-7 Press Release
